A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2001
10/18/2001	WO2001077149A2 Regulation of human cyslt2-like gpcr protein
10/18/2001	WO2001077139A1 8ss-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS
10/18/2001	WO2001077138A1 8β-SUBSTITUTED-11β-PENTYL- AND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES
10/18/2001	WO2001077133A1 1-carboxymethyl analogues of lipid a
10/18/2001	WO2001077115A1 Antitumoral ecteinascidin derivatives
10/18/2001	WO2001077114A1 Inhibitors of prenyl-protein transferase
10/18/2001	WO2001077113A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
10/18/2001	WO2001077111A1 Pyrazolo-triazine derivatives as ligands for gaba receptors
10/18/2001	WO2001077110A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
10/18/2001	WO2001077109A2 Sodium salt of an azo derivative of 5-aminosalicylic acid
10/18/2001	WO2001077108A1 Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
10/18/2001	WO2001077105A1 Dual molecules containing a peroxide derivative, synthesis and therapeutic applications thereof
10/18/2001	WO2001077104A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
10/18/2001	WO2001077101A1 Chemical compounds
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077097A2 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
10/18/2001	WO2001077094A1 Percyquinnin, a process for its production and its use as a pharmaceutical
10/18/2001	WO2001077093A1 Estrogen agonist/antagonist metabolites
10/18/2001	WO2001077092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/18/2001	WO2001077089A1 New neurokinin antagonists for use as medicaments
10/18/2001	WO2001077087A1 Novel compounds
10/18/2001	WO2001077086A1 SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
10/18/2001	WO2001077085A1 Quinazoline compounds
10/18/2001	WO2001077080A2 Pyrazole compounds having anti proliferative activity
10/18/2001	WO2001077079A2 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
10/18/2001	WO2001077074A1 Process for preparing optically active aminopentane derivatives
10/18/2001	WO2001077073A1 Cathepsin cysteine protease inhibitors
10/18/2001	WO2001077072A2 Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
10/18/2001	WO2001077069A1 Naphthamide neurokinin antagonists for use as medicaments
10/18/2001	WO2001077057A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001077055A2 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001076758A1 Concentric tubular centrifuge
10/18/2001	WO2001076715A2 Method for the fractionation of oil and polar lipid-containing native raw materials
10/18/2001	WO2001076694A1 Inhibitors of prenyl-protein transferase
10/18/2001	WO2001076693A1 Inhibitors of prenyl-protein transferase
10/18/2001	WO2001076649A1 An injectable bone mineral substitute material
10/18/2001	WO2001076644A2 Lipid-based systems for targeting diagnostic agents
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076634A1 Oral delivery method and composition for solid medications or dietary supplements
10/18/2001	WO2001076632A1 Formulation for the prevention of cardiovascular disease
10/18/2001	WO2001076631A2 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
10/18/2001	WO2001076629A1 Soluble beta amyloid precursor protein secretion promoters
10/18/2001	WO2001076627A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	WO2001076614A1 Remedies
10/18/2001	WO2001076610A1 Pharmaceutical composition with a content of calcium or mixture of calcium and vitamin d or mixture of calcium and magnesium in a new formulation
10/18/2001	WO2001076609A1 Production of polygalacturonides and their use as food additives
10/18/2001	WO2001076608A1 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients
10/18/2001	WO2001076607A1 Dry syrup containing theophylline sustained release microcapsules
10/18/2001	WO2001076606A2 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
10/18/2001	WO2001076605A1 Minoxidil-containing preparations
10/18/2001	WO2001076604A1 Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
10/18/2001	WO2001076602A1 Apomorphine derivatives and methods for their use
10/18/2001	WO2001076601A2 Pharmaceutical compositions comprising salmeterol and ipratropium
10/18/2001	WO2001076600A2 Inhibition of cytokine generation
10/18/2001	WO2001076599A1 Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free base form
10/18/2001	WO2001076597A2 A method of administering an antitumour compound using a polymer-camptothecin conjugate
10/18/2001	WO2001076596A1 Medicine for treating traumatic brain injury and other neuronal disorders
10/18/2001	WO2001076595A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
10/18/2001	WO2001076594A1 Antimicrobial coatings
10/18/2001	WO2001076593A2 Bile secretion promoting composition a 15-keto prostaglandin
10/18/2001	WO2001076592A1 Compositions and methods for promoting neural regeneration
10/18/2001	WO2001076591A1 Treatment of pulmonary disorders by inducing alveoli formation
10/18/2001	WO2001076590A2 Treatment for benign positional vertigo using antiepileptics
10/18/2001	WO2001076589A1 Dermatological use and a dermatological preparation
10/18/2001	WO2001076588A1 Method to inhibit lipoxygenase and cancer cell proliferation
10/18/2001	WO2001076586A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	WO2001076585A2 Use of thiamphenicol for the treatment of chlamydia pneumoniae infections
10/18/2001	WO2001076584A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	WO2001076583A1 Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes
10/18/2001	WO2001076582A1 Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
10/18/2001	WO2001076581A1 Curcumin compositions
10/18/2001	WO2001076579A1 Treatment of skin damage using olive oil polyphenols
10/18/2001	WO2001076578A2 Treatment of icu-associated hypocalcemia with vitamin d compounds
10/18/2001	WO2001076577A2 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
10/18/2001	WO2001076576A2 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
10/18/2001	WO2001076575A2 The treatment of respiratory diseases
10/18/2001	WO2001076574A2 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
10/18/2001	WO2001076573A2 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076571A2 Use of sabcomeline in the treatment of anxiety
10/18/2001	WO2001076570A2 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses
10/18/2001	WO2001076569A2 An improved pt(iv) antitumor agent
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076567A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	WO2001076563A1 Method for stabilising particle size distribution of a powdery active principle dispersed in a liquid and uses thereof
10/18/2001	WO2001076556A2 Lipid-based drug delivery systems against parasitic infections
10/18/2001	WO2001076555A2 Lipid-based drug delivery systems for topical application
10/18/2001	WO2001076554A2 Drug delivery composition and device
10/18/2001	WO2001076551A1 Cosmetic or pharmaceutical composition containing a sesquiterpene lactone
10/18/2001	WO2001076542A1 Hair growth stimulant compositions
10/18/2001	WO2001076541A1 Hair growth stimulant compositions
10/18/2001	WO2001076538A1 Compositions for metabolic protection and repair of lips
10/18/2001	WO2001076537A1 Treatment of skin damage using polyenylphosphatidylcholine
10/18/2001	WO2001076531A2 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001076451A2 Diagnosis of diseases associated with metabolism
10/18/2001	WO2001076394A1 Starch sub-types and lipid metabolism
10/18/2001	WO2001076385A1 Method for the fractionation of oil and polar lipid-containing native raw materials using alcohol and centrifugation
10/18/2001	WO2001076370A2 Anthelmintic combinations

1 ... 5987 5988 5989 5990 5991 5992 5993 5994 5995 5996 5997 5998 5999 6000 6001 6002 6003 6004 6005 6006 6007 ... 7860